Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.72 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941982 | 1.00 | CTSK (0.72) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL13909124 | 0.95 | CTSK (0.63) | CTSKCTSSALDH1A1CTSLCTSB | |
| SCHEMBL4041217 | 0.83 | CTSK (1.00) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL4219738 | 0.83 | CTSK (1.00) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL5941346 | 0.83 | CTSK (1.00) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL4219737 | 0.83 | CTSK (1.00) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL5942856 | 0.83 | CTSK (0.70) | CTSKCTSSALDH1A1KDM4EGAA | |
| SCHEMBL8349856 | 0.81 | CTSK (0.62) | CTSKALDH1A1KDM4EGAAHPGD | |
| SCHEMBL4048380 | 0.78 | CTSK (0.64) | CTSKCTSS | |
| SCHEMBL5941514 | 0.78 | CTSK (0.64) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885ALDH1A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.